LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease

Shuoyan Tan; Huanxiang Liu; Xiaojun Yao

doi:10.1021/acschemneuro.4c00657

LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease

Shuoyan Tan, Huanxiang Liu, Xiaojun Yao

Faculty of Applied Sciences

Research output: Contribution to journal › Review article › peer-review

Abstract

Parkinson’s disease (PD) is one of the most prevalent neurodegenerative disorders, with current treatments offering only temporary symptomatic relief. There is an urgent need for the development of novel therapeutic approaches. Abnormal increases in LRRK2 kinase activity have been identified in both sporadic and familial PD patients, suggesting that inhibiting LRRK2 kinase activity presents a promising avenue for the pursuit of effective PD treatment strategies. In this Viewpoint, we discuss the exciting new insights regarding the development of LRRK2 kinase inhibitors as a treatment for Parkinson’s disease.

Original language	English
Pages (from-to)	4092-4094
Number of pages	3
Journal	ACS Chemical Neuroscience
Volume	15
Issue number	22
DOIs	https://doi.org/10.1021/acschemneuro.4c00657
Publication status	Published - 20 Nov 2024

Keywords

Leucine-rich repeat kinase 2
Parkinson’s disease
kinase inhibitor

Access to Document

10.1021/acschemneuro.4c00657

Cite this

@article{cb69579b639f41b2acfa4e93dccfac4a,

title = "LRRK2 Inhibitors as Promising Treatment for Parkinson{\textquoteright}s Disease",

abstract = "Parkinson{\textquoteright}s disease (PD) is one of the most prevalent neurodegenerative disorders, with current treatments offering only temporary symptomatic relief. There is an urgent need for the development of novel therapeutic approaches. Abnormal increases in LRRK2 kinase activity have been identified in both sporadic and familial PD patients, suggesting that inhibiting LRRK2 kinase activity presents a promising avenue for the pursuit of effective PD treatment strategies. In this Viewpoint, we discuss the exciting new insights regarding the development of LRRK2 kinase inhibitors as a treatment for Parkinson{\textquoteright}s disease.",

keywords = "Leucine-rich repeat kinase 2, Parkinson{\textquoteright}s disease, kinase inhibitor",

author = "Shuoyan Tan and Huanxiang Liu and Xiaojun Yao",

note = "Publisher Copyright: {\textcopyright} 2024 American Chemical Society.",

year = "2024",

month = nov,

day = "20",

doi = "10.1021/acschemneuro.4c00657",

language = "English",

volume = "15",

pages = "4092--4094",

journal = "ACS Chemical Neuroscience",

issn = "1948-7193",

publisher = "American Chemical Society",

number = "22",

}

TY - JOUR

T1 - LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease

AU - Tan, Shuoyan

AU - Liu, Huanxiang

AU - Yao, Xiaojun

PY - 2024/11/20

Y1 - 2024/11/20

N2 - Parkinson’s disease (PD) is one of the most prevalent neurodegenerative disorders, with current treatments offering only temporary symptomatic relief. There is an urgent need for the development of novel therapeutic approaches. Abnormal increases in LRRK2 kinase activity have been identified in both sporadic and familial PD patients, suggesting that inhibiting LRRK2 kinase activity presents a promising avenue for the pursuit of effective PD treatment strategies. In this Viewpoint, we discuss the exciting new insights regarding the development of LRRK2 kinase inhibitors as a treatment for Parkinson’s disease.

AB - Parkinson’s disease (PD) is one of the most prevalent neurodegenerative disorders, with current treatments offering only temporary symptomatic relief. There is an urgent need for the development of novel therapeutic approaches. Abnormal increases in LRRK2 kinase activity have been identified in both sporadic and familial PD patients, suggesting that inhibiting LRRK2 kinase activity presents a promising avenue for the pursuit of effective PD treatment strategies. In this Viewpoint, we discuss the exciting new insights regarding the development of LRRK2 kinase inhibitors as a treatment for Parkinson’s disease.

KW - Leucine-rich repeat kinase 2

KW - Parkinson’s disease

KW - kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85209204103&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.4c00657

DO - 10.1021/acschemneuro.4c00657

M3 - Review article

C2 - 39487783

AN - SCOPUS:85209204103

SN - 1948-7193

VL - 15

SP - 4092

EP - 4094

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

IS - 22

ER -

LRRK2 Inhibitors as Promising Treatment for Parkinson’s Disease

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this